1. Academic Validation
  2. Toppling the HAT to Treat Lethal Prostate Cancer

Toppling the HAT to Treat Lethal Prostate Cancer

  • Cancer Discov. 2021 May;11(5):1011-1013. doi: 10.1158/2159-8290.CD-21-0184.
Reyaz Ur Rasool 1 Ramakrishnan Natesan 1 Irfan A Asangani 2 3
Affiliations

Affiliations

  • 1 Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • 2 Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. asangani@upenn.edu.
  • 3 Department of Cancer Biology, Abramson Family Cancer Research Institute, Penn Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract

In this issue of Cancer Discovery, Welti and colleagues demonstrate a positive correlation between the expression of the Histone Acetyltransferase paralogs CBP and p300 with increased Androgen Receptor (AR) signaling and androgen deprivation therapy resistance in advanced prostate Cancer. CCS1477, a selective inhibitor of p300/CBP bromodomain, disrupts AR- and MYC-regulated gene expression, suppresses tumor growth in vivo in multiple castration-resistant prostate Cancer xenograft models, and modulates biomarker expression in early clinical evaluation, providing a novel therapeutic approach for AR-addicted advanced prostate Cancer.See related article by Welti et al., p. 1118.

Figures
Products